Search
Akebia Therapeutics Inc
AKBAAdd to Watchlist
1.070USD
+0.050+4.90%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
287.04MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Akebia Therapeutics Inc is 9.20, ranking 2 out of 157 in the Pharmaceuticals industry. The average price target is 5.00, with a high of 6.00 and a low of 5.00.
Analyst Rating
Based on
5
analysts
Strong Buy
Current Rating
4.200
Target Price
+311.76%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
175
Total
6
Median
8
Average
Company name
Ratings
Analysts
Akebia Therapeutics Inc
AKBA
5
Amgen Inc
AMGN
38
Biogen Inc
BIIB
38
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
34
1
2
3
...
35
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Akebia Therapeutics Inc's expected revenue for the next quarter?
Akebia Therapeutics Inc's expected revenue is 50.94M.
What is Akebia Therapeutics Inc's price target?
Analysts forecast that Akebia Therapeutics Inc's price target is USD 5.00, with the highest forecast at USD 6.00 and the lowest forecast at USD 5.00.
How have Akebia Therapeutics IncAKBA's recent earnings per share performed?
The market expectation was USD -0.03, while Akebia Therapeutics IncAKBA's earnings per share (EPS) for the previous quarter was USD -0.05. EPS for the next quarter is expected at USD -0.04.
What is the analyst rating for Akebia Therapeutics Inc?
Based on the ratings of Akebia Therapeutics Inc's stock from 5 analysts, most analysts support a STRONG BUY trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as STRONG BUY. Please note that this is not trading advice. You still need to conduct your own analysis.
